Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

<p>Abstract</p> <p>Background</p> <p>EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypot...

Full description

Bibliographic Details
Main Authors: Wang Fen, Wang Shuhang, Wang Zhijie, Duan Jianchun, An Tongtong, Zhao Jun, Bai Hua, Wang Jie
Format: Article
Language:English
Published: BMC 2012-08-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:http://www.jeccr.com/content/31/1/65